Literature DB >> 35654037

Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease.

Nikhil Panicker1, Tae-In Kam2, Hu Wang3, Stewart Neifert4, Shih-Ching Chou5, Manoj Kumar1, Saurav Brahmachari1, Aanishaa Jhaldiyal6, Jared T Hinkle7, Fatih Akkentli4, Xiaobo Mao1, Enquan Xu1, Senthilkumar S Karuppagounder1, Eric T Hsu8, Sung-Ung Kang1, Olga Pletnikova9, Juan Troncoso10, Valina L Dawson11, Ted M Dawson12.   

Abstract

Parkinson's disease (PD) is mediated, in part, by intraneuronal accumulation of α-synuclein aggregates andsubsequent death of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc). Microglial hyperactivation of the NOD-like receptor protein 3 (NLRP3) inflammasome has been well-documented in various neurodegenerative diseases, including PD. We show here that loss of parkin activity in mouse and human DA neurons results in spontaneous neuronal NLRP3 inflammasome assembly, leading to DA neuron death. Parkin normally inhibits inflammasome priming by ubiquitinating and targeting NLRP3 for proteasomal degradation. Loss of parkin activity also contributes to the assembly of an active NLRP3 inflammasome complex via mitochondrial-derived reactive oxygen species (mitoROS) generation through the accumulation of another parkin ubiquitination substrate, ZNF746/PARIS. Inhibition of neuronal NLRP3 inflammasome assembly prevents degeneration of DA neurons in familial and sporadic PD models. Strategies aimed at limiting neuronal NLRP3 inflammasome activation hold promise as a disease-modifying therapy for PD.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Caspase-1; NLRP3; PARIS; Parkinson’s disease; ZNF746; inflammasome; neurodegeneration; parkin; ubiquitination

Mesh:

Substances:

Year:  2022        PMID: 35654037      PMCID: PMC9357148          DOI: 10.1016/j.neuron.2022.05.009

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   18.688


  47 in total

1.  Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.

Authors:  Kelvin C Luk; Victoria Kehm; Jenna Carroll; Bin Zhang; Patrick O'Brien; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

Review 2.  Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection.

Authors:  Sheila K Pirooznia; Liana S Rosenthal; Valina L Dawson; Ted M Dawson
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 25.468

3.  Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations.

Authors:  Helen I Woodroof; Joe H Pogson; Mike Begley; Lewis C Cantley; Maria Deak; David G Campbell; Daan M F van Aalten; Alexander J Whitworth; Dario R Alessi; Miratul M K Muqit
Journal:  Open Biol       Date:  2011-11       Impact factor: 6.411

4.  Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration.

Authors:  Daniel A Stevens; Yunjong Lee; Ho Chul Kang; Byoung Dae Lee; Yun-Il Lee; Aaron Bower; Haisong Jiang; Sung-Ung Kang; Shaida A Andrabi; Valina L Dawson; Joo-Ho Shin; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

5.  Distinct roles of TLR2 and the adaptor ASC in IL-1beta/IL-18 secretion in response to Listeria monocytogenes.

Authors:  Nesrin Ozören; Junya Masumoto; Luigi Franchi; Thirumala-Devi Kanneganti; Mathilde Body-Malapel; Ilkim Ertürk; Rajesh Jagirdar; Li Zhu; Naohiro Inohara; John Bertin; Anthony Coyle; Ethan P Grant; Gabriel Núñez
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

6.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.

Authors:  Susannah D Brydges; James L Mueller; Matthew D McGeough; Carla A Pena; Amirhossein Misaghi; Chhavi Gandhi; Chris D Putnam; David L Boyle; Gary S Firestein; Anthony A Horner; Pejman Soroosh; Wendy T Watford; John J O'Shea; Daniel L Kastner; Hal M Hoffman
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

Review 7.  Parkin and PINK1: much more than mitophagy.

Authors:  Leslie A Scarffe; Daniel A Stevens; Valina L Dawson; Ted M Dawson
Journal:  Trends Neurosci       Date:  2014-04-13       Impact factor: 13.837

8.  Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease.

Authors:  Sonja Kriks; Jae-Won Shim; Jinghua Piao; Yosif M Ganat; Dustin R Wakeman; Zhong Xie; Luis Carrillo-Reid; Gordon Auyeung; Chris Antonacci; Amanda Buch; Lichuan Yang; M Flint Beal; D James Surmeier; Jeffrey H Kordower; Viviane Tabar; Lorenz Studer
Journal:  Nature       Date:  2011-11-06       Impact factor: 49.962

9.  Slc6a3-dependent expression of a CAPS-associated Nlrp3 allele results in progressive behavioral abnormalities and neuroinflammation in aging mice.

Authors:  Katharine M von Herrmann; Faith L Anderson; Eileen M Martinez; Alison L Young; Matthew C Havrda
Journal:  J Neuroinflammation       Date:  2020-07-17       Impact factor: 8.322

10.  NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.

Authors:  Michael T Heneka; Markus P Kummer; Andrea Stutz; Andrea Delekate; Stephanie Schwartz; Ana Vieira-Saecker; Angelika Griep; Daisy Axt; Anita Remus; Te-Chen Tzeng; Ellen Gelpi; Annett Halle; Martin Korte; Eicke Latz; Douglas T Golenbock
Journal:  Nature       Date:  2012-12-19       Impact factor: 49.962

View more
  2 in total

Review 1.  The Significance of NLRP Inflammasome in Neuropsychiatric Disorders.

Authors:  Yao Shen; Liyin Qian; Hu Luo; Xiaofang Li; Yuer Ruan; Runyue Fan; Zizhen Si; Yunpeng Chen; Longhui Li; Yu Liu
Journal:  Brain Sci       Date:  2022-08-10

Review 2.  Interaction between autophagy and the NLRP3 inflammasome in Alzheimer's and Parkinson's disease.

Authors:  Ranran Lu; Lijie Zhang; Xinling Yang
Journal:  Front Aging Neurosci       Date:  2022-10-03       Impact factor: 5.702

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.